HLB bioStep

HLB바이오스텝 · 278650

Health Care Biotechnology · KOSDAQ

Small-cap

Market cap US$40.9M (₩56.4B)

Overview

HLB bioStep runs preclinical contract research, meaning it tests drug candidates on laboratory animals on behalf of pharmaceutical and biotech companies before those drugs enter human trials.

Its customers include pharmaceutical firms, biotech ventures, research institutes, and universities listed on KOSDAQ, Korea's tech and small-cap exchange. The company's core service is efficacy testing, confirming whether a drug candidate actually works, and it also designs and builds animal-laboratory facilities and supplies lab consumables to clients.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$53.7M

▲ +27.3% YoY

Operating profit · FY2025

−US$6.2M

Loss narrowed

Net income · FY2025

−US$14.7M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$38.3M(₩52.8B)	US$42.2M(₩58.2B)	US$53.7M(₩74.1B)
Operating profit	−US$924.8K(−₩1.3B)	−US$9.4M(−₩13B)	−US$6.2M(−₩8.6B)
Net income	−US$39.3K(−₩54.2M)	−US$7M(−₩9.7B)	−US$14.7M(−₩20.3B)

Revenue

FY2023US$38.3M
FY2024US$42.2M
FY2025US$53.7M

Operating profit

FY2023−US$924.8K
FY2024−US$9.4M
FY2025−US$6.2M

Net income

FY2023−US$39.3K
FY2024−US$7M
FY2025−US$14.7M

Key ratios (FY2025)

ROE

-20.1%

Debt/Eq

54.1%

Op. margin

-11.6%

Net margin

-27.4%

Rev. YoY

▲ +27.3%

Why it matters

HLB bioStep expanded its toxicology capabilities by acquiring HLB바이오코드 (formerly Croen) as a subsidiary, adding regulated GLP-standard toxicity testing to its existing non-GLP preclinical services.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?